ZURICH (Reuters) - Switzerland-based PSquared Asset Management on Wednesday unveiled a stake of more than 4% in Qiagen QIA.DE, adding it would not tender its shares into a $12.9 billion offer by U.S. laboratory equipment supplier Thermo Fisher TMO.N.
“PSquared believes that the current cash offer by Thermo Fisher at 43 euros ($50.45) per share materially undervalues Qiagen on a standalone basis,” the fund said in response to a Reuters request.
“PSquared will not tender any shares into the current offer.”
Hedge fund Davidson Kempner, which says it owns more than 5% of Qiagen, a day earlier said it would not tender its shares into the offer, adding a price of between 48 euros and 52 euros a share was more appropriate.
Reporting by Paul Arnold and Oliver Hirt; Writing by Christoph Steitz; Editing by Michelle Martin
Our Standards: The Thomson Reuters Trust Principles.